Business
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), today announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (“efti”) in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned in
About this update from Immutep Ltd
[{"type":"image","alt":"Immutep Limited","displaySize":"","headline":null,"caption":"Immutep Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/a65b2254e4fad33e9b06532c1096f80c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2K_jS0oItbqmH4M0dhn7Sw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a65b2254e4fad33e9b06532c1096f80c","width":300,"height":103}},"lazy":false},{"type":"text","content":"Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis","length":111,"tagName":"p"},{"type":"text","content":"SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), today announced that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa (“efti”) in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol.","length":450,"tagName":"p"},{"type":"text","content":"Based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility.","length":128,"tagName":"p"},{"type":"text","content":"In response to the IDMC’s recommendation, enrolment in the study will be halted and the Company will implement an orderly wind down of the study, including appropriate patient follow up and site close out in accordance with regulatory and ethical obligations.","length":259,"tagName":"p"},{"type":"text","content":"“We are very disappointed and surprised with the outcome of the futility analysis, in light of efti’s performance in every other clinical trial” said Marc Voigt, Chief Executive Officer. “We would like to thank the patients, investigators, and clinical teams who contributed to this important study. We are currently conducting a comprehensive review of the available data to better understand the results and determine the appropriate next steps for the program.”","length":464,"tagName":"p"},{"type":"text","content":"Immutep remains focused on advancing its pipeline of innovative therapies including efti. Following the discontinuation of TACTI-004, Immutep now anticipate...